Sharemaestro Newsreel

Arrowstreet Capital Limited Partnership Buys Shares of 102,643 Dr. Reddy's Laboratories Ltd $RDY

Arrowstreet Capital Limited Partnership recently acquired 102,643 shares of Dr. Reddy's Laboratories (NYSE:RDY), valued at approximately $1.42 million. This move comes as other institutional investors also increased their holdings in the company. Despite these purchases, Dr. Reddy's stock has faced downward pressure, with shares …

Amylyx Pharmaceuticals Narrows Q2 2026 Loss to -$0.39/Share

Amylyx Pharmaceuticals reported a wider-than-expected net loss of $0.39 per share for Q2 2026, missing the Street's estimate of $0.37, yet this represented a 15.2% improvement from the prior year. Despite the miss, the stock remained flat, and analysts maintain a bullish outlook with …

Emergent BioSolutions laying off dozens, shedding real estate as Narcan competition strains profits

Emergent BioSolutions is undergoing significant restructuring, including layoffs and real estate divestment, to cut costs. These measures are a response to increased competition for its key product, Narcan, an over-the-counter opioid overdose reversal spray. The company has been implementing these changes since Joe Papa …

Ironwood Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IRWD) 2026-08-06

Alkermes plc $ALKS Shares Acquired by California State Teachers Retirement System

California State Teachers Retirement System increased its stake in Alkermes plc (NASDAQ:ALKS) by 23.5% in the first quarter, now holding 183,795 shares valued at $6.5 million. Institutional investors own 95.21% of the company, and analysts maintain a "Moderate Buy" rating with an average price …

Perrigo Company Delivers 42.9% Q2 2026 Upside, Revenue Down 3%

Perrigo Company plc reported Q2 2026 adjusted earnings of $0.50 per share, significantly exceeding analysts' $0.35 forecast by 42.9%. Despite this strong earnings beat, the company's revenue declined by 3.2% year-over-year to $1.02 billion, with organic net sales falling by 1.3%. Management provided a …

Here's What Analysts Are Forecasting For Pacira BioSciences, Inc. (NASDAQ:PCRX) After Its Second-Quarter Results

This article examines the latest analyst forecasts for Pacira BioSciences, Inc. (NASDAQ:PCRX) following its second-quarter results. It provides an overview of the consensus earnings estimates and how they have changed over time, along with an assessment of the company's financial performance and future prospects …

Prestige Consumer Healthcare (NYSE: PBH) expands with $1,045.0M wellness deal

Prestige Consumer Healthcare Inc. (NYSE: PBH) reported its Q1 2027 earnings, revealing a 6.5% increase in total revenues to $265.7 million for the quarter ended June 30, 2026, primarily driven by the $1,045.0 million acquisition of the OTC Wellness Business, including the Breathe Right …

Earnings call transcript: Prestige Consumer beats Q1 2026 estimates as stock edges higher

Prestige Consumer Healthcare reported stronger-than-expected Q1 fiscal 2027 results, with adjusted EPS of $0.98 and revenue of $265.7 million, both exceeding analyst estimates. The company saw organic revenue growth of 3.2% and a record adjusted free cash flow of $83.7 million, while integrating the …

Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates

Perrigo (PRGO) reported strong second-quarter 2026 results, with All In adjusted earnings per share of 50 cents significantly beating the Zacks Consensus Estimate of 31 cents. Despite a decline in All In net sales to $1.02 billion, this still marginally surpassed the $1 billion …

Emergent BioSolutions | 10-Q: Q2 2026 Earnings Report

This article provides the Q2 2026 earnings report for Emergent BioSolutions. It is a quarterly filing (10-Q) that details the company's financial performance during the second quarter of 2026.

Journey Medical Corp (DERM) Earnings Forecast: Future EPS & Revenue Growth Estimates

Journey Medical Corp (DERM) has an earnings forecast score of 8.00, ranking 58th in the Pharmaceuticals industry, with an average price target of $13.00 from analysts. Four analysts currently rate DERM as a "Buy," anticipating a significant upside. The company's expected revenue for the …

Why Is Tilray Brands (NASDAQ:TLRY) In The Spotlight This Week?

Tilray Brands (NASDAQ:TLRY) is currently in focus due to its diversified operations spanning cannabis, beverages, and wellness products, amidst market volatility. A key factor is a mid-August deadline set by the U.S. Drug Enforcement Administration for submissions regarding moving cannabis to a less restrictive …

Viatris Looks to New Launches, Pipeline Progression, and Cost Savings for Long-Term Growth

Viatris, one of the largest generic drug manufacturers globally, aims for long-term growth through new product launches, pipeline progression, and cost savings. While generics face erosion in developed markets, the company plans to focus on complex generics to mitigate pricing and margin pressures. This …

Form 4 KAMADA LTD For: 6 August By Investing.com

This article from Investing.com reports on a Form 4 filing for KAMADA LTD related to August 6th. Form 4 filings are typically used to report changes in beneficial ownership of securities by company insiders. The article includes the stock symbol KMDA and notes a …

Kamada Ltd Director Uri Botzer Granted 30,000 Stock Options Under 2011 Plan

Uri Botzer, a director of Kamada Ltd, has been granted 30,000 employee stock options. This acquisition was reported in a statement of changes in beneficial ownership filed on August 6, 2026, with the options granted on August 5, 2026. This action falls under the …

Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

Viatris has agreed to sell its Tyrvaya nasal spray business to Harrow Inc. for up to $100 million, a move that will allow Viatris to focus on high-potential growth areas like complex generics and transdermal products, and continued investment in the Greater China market. …

Viatris Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:VTRS) 2026-08-06

Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (NYSE: HIMS) of an Ongoing Investigation Into Potential Securities Law Violations

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Hims & Hers Health, Inc. following a lawsuit filed by the FTC and California/Utah consumer protection agencies. The lawsuit alleges that Hims & Hers failed to clearly disclose prescription charges, made it …

BioCryst WARN filing reveals 47 jobs affected by Birmingham research center closure

BioCryst Pharmaceuticals will lay off 47 employees starting October 7, 2026, as it closes its Birmingham-area Discovery Center of Excellence. This decision is part of a strategic shift to focus on externally sourced innovation and reduce operating costs, with the company lowering its 2026 …

Wedbush Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead

Takeda's oral orexin receptor agonist, oveporexton (marketed as Orzeyful), has received FDA approval for narcolepsy type 1, making it the first disease-modifying therapy for the condition. The drug targets the root cause of narcolepsy by binding to the orexin receptor 2, improving wakefulness and …

Evolus Inc (EOLS) News, Articles, Events & Latest Updates

This article provides a compilation of recent news, articles, and updates concerning Evolus Inc (EOLS). Key highlights include Evolus reporting strong Q2 2026 financial results with positive adjusted EBITDA, expanding partnerships, and announcing future earnings report dates. The company also reported inducement grants of …

Options Exercise Update At Kamada: Lilach Payorski Engages, Resulting In $0

Lilach Payorski, a Board Member at Kamada (NASDAQ: KMDA), recently exercised stock options for 0 shares, resulting in a value of $0. This information was disclosed in an SEC Form 4 filing on August 6, 2026. The article also provides a brief overview of …

Options Exercise Activity Initiated By Leon Recanati At Kamada Worth $0

Leon Recanati, a Director at Kamada (NASDAQ: KMDA), executed an options exercise for 0 shares, valued at $0, as revealed in an SEC filing on August 6, 2026. Despite this nominal transaction, the article highlights Kamada's strong financial performance, including a revenue growth rate …

Citing Gaza war, pharma giant Teva doesn't want US jurors in price-fixing trial to know it's Israeli

Teva Pharmaceuticals has requested a US judge to prevent insurer Humana from revealing its Israeli nationality to jurors in an upcoming price-fixing trial. The company argues that strong public sentiment regarding the Gaza war could prejudice the proceedings and hinder its ability to receive …

Takeda approval ushers in new wave of sleep drugs

The FDA has approved Takeda's Orzeyful, a drug for Type 1 narcolepsy that targets orexin-2 protein. This approval marks the entry of a potentially multibillion-dollar class of sleep medicines. Orzeyful's launch is pending DEA scheduling, while other companies like Alkermes and Eli Lilly are …

Viatris stock hits 52-week high at 18.27 USD

Viatris Inc. (VTRS) stock reached a 52-week high of $18.07, demonstrating strong investor confidence with a 109.7% return over the past year and a market capitalization of $20.55 billion. InvestingPro analysis suggests the stock is undervalued with a "GOOD" financial health score. Recent positive …

Teva seeks to keep Israel ties from jury, cites Gaza war

Teva Pharmaceuticals has asked a U.S. judge to prevent insurer Humana from informing jurors that Teva is an Israeli company during an upcoming drug price-fixing trial. Teva argues that strong public sentiment surrounding the Gaza war could prejudice the proceedings and hinder its ability …

Gelteq Ltd (GELS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Gelteq Ltd (GELS), focusing on future EPS and revenue growth estimates. It includes current stock performance, market capitalization, and a comparison with peer pharmaceutical companies. The financial forecasting section indicates data available for EPS, Revenue, Net Profit, …

Is Ironwood Pharmaceuticals (IRWD) Undervalued After Q2 Earnings

Why Elanco Animal Health (ELAN) Stock Is Down Today

Takeda wins U.S. FDA approval for narcolepsy drug ORZEYFUL

Takeda Pharmaceutical has received U.S. FDA approval for ORZEYFUL (oveporexton) to treat adults with narcolepsy type 1, making it the first approved orexin agonist for the disorder. The approval, granted on August 5, 2026, is based on positive Phase 3 trial results showing significant …

Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful

Takeda has received FDA approval for Orzeyful (oveporexton), a first-in-class, twice-daily tablet for adults with narcolepsy type 1 (NT1). This treatment addresses the root cause of the condition by mimicking the body's orexin cycle. Takeda anticipates peak sales for Orzeyful to be between $2 …

ETON Q2'26 Earnings: revenue estimate is 27.11M USD

Eton Pharmaceuticals, Inc. (ETON) is scheduled to release its Q2'26 earnings on August 13, after market close at 4:05 PM ET (8:05 PM UTC). Analysts estimate revenue to be $27.11 million and earnings per share (EPS) at $0.16 for the quarter. The article provides …

Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut